Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011).
Inspired
1 other identifier
observational
966
1 country
2
Brief Summary
Crohn's disease (CD) and ulcerative colitis (UC) are chronic Inflammatory Bowel Disease (IBD) and may affect all segments of the digestive tract.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2015
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 12, 2015
CompletedFirst Posted
Study publicly available on registry
March 18, 2015
CompletedStudy Start
First participant enrolled
May 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2019
CompletedApril 27, 2026
April 1, 2026
3.9 years
March 12, 2015
April 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Cumulative incidence of surgical resection in CD and colectomy in pediatric UC
Cumulative incidence of surgical resection in CD and colectomy in pediatric ulcerative colitis, depending on the date of diagnosis and the possibility of using immunosuppressants and / or anti-TNFs.
end of follow up
Secondary Outcomes (15)
Disease extension according to Montreal classification
end of follow up
Treatment during the follow up
end of follow up
information about occurrence of postoperative complications
end of follow up
Weight and size
end of follow up
Hospitalisations
end of follow up
- +10 more secondary outcomes
Eligibility Criteria
Pediatric IBD patients in the area of EPIMAD registry Age of diagnosis \< 17 years
You may qualify if:
- Patients in the pediatric cohort EPIMAD registry with a diagnosis of CD or UC or probable between 1988 and 2011.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
CHRU Lille
Lille, Lille, 59000, France
CHU Rouen
Rouen, Rouen, 7700, France
Related Publications (1)
Ley D, Leroyer A, Dupont C, Sarter H, Bertrand V, Spyckerelle C, Guillon N, Wils P, Savoye G, Turck D, Gower-Rousseau C, Fumery M; Epimad Group. New Therapeutic Strategies Have Changed the Natural History of Pediatric Crohn's Disease: A Two-Decade Population-Based Study. Clin Gastroenterol Hepatol. 2022 Nov;20(11):2588-2597.e1. doi: 10.1016/j.cgh.2022.01.051. Epub 2022 Feb 4.
PMID: 35131345RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Mathurin Fumery, Doctor
CHU Amiens France
- STUDY DIRECTOR
Jean-Louis Dupas, professor
CHU Amiens France
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 12, 2015
First Posted
March 18, 2015
Study Start
May 1, 2015
Primary Completion
April 1, 2019
Study Completion
April 1, 2019
Last Updated
April 27, 2026
Record last verified: 2026-04